Argenx Se Adr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Argenx stock lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of.

Noord hollandArticle normalEquity marketsArgenx seBe argxArgenx se adr